Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcoma

Phase 2

Recruiting

• Conditions: rhabdomyosarcoma

• Registration Number: JPRN-UMIN000020891
• Lead Sponsor: Japan Rhabdomyosarcoma Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with central nervus system primary or metastatic tumors 2) Patients with synchronous or metachrounous concomitant malignancies 3) Patients with Charcot-Marie-Tooth disease or varicella 4) Patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 5) Patients with contraindication of drugs used in this study 6) Female patints who are pregnant or breastfeeding mother or patients considering pregnancy 7) Patients with any other inappropriate conditon judged by physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified